E6-specific inhibitors offer a unique, strategic approach for treating HPV-HNSCC

Oncotarget published “A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas” which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.